Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > Everolimus > Printer-friendly PDF

Everolimus

Trade Name: Afinitor Manufacturer/Distributor: 1-800-363-8883 or [email protected] Classification: Antineoplastic agent ATC Class: L04AA18 Everolimus Status: active Notice of Compliance (yyyy/mm/dd): 2009/12/14 Date Marketed in Canada (yyyy/mm/dd): 2010/02/12 Presentation: Tablets: 5 mg; DIN: 02339501 Tablets: 10 mg; DIN: 02339528 Comments: For treatment of metastatic of clear cell morphology, after failure of initial treatment with either sunitnib or . Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ?

Search Terms:

Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Ozempic Incretin mimetic 2018/02/22 Semaglutide Rybelsus Incretin mimetic 2020/04/19 Sibutramine Meridia 2010/10/08 cGMP-Specific Sildenafil citrate Revatio IV Phosphodiesterase Type 5 2010/08/31 Inhibitor Silodosin Rapaflo Alpha-1 adrenergic blocker 2012/03/05 Siltuximab Sylvant Immunosuppressive agent 2015/01/02 Mayzent Immunomodulatory agent 2020/04/24 Sitagliptin Januvia Hypoglycemic agent 2012/11/20 Sitagliptin and Janumet Hypoglycemic agent 2009/09/24 metformin receptor Sitaxsentan Thelin antagonist Sodium zirconium Lokelma Potassium binder 2019/10/17 cyclosilicate Sofosbuvir + Epclusa Antiviral agent 2016/07/11 velpatasvir Sofosbuvir + Antiviral agent for treatment velpatasvir + Vosevi of chronic hepatitis C 2017/09/18 voxilaprevir infection Odomzo Antineoplastic agent 2020/06/11 Stiripentol Diacomit Antiepileptic 2014/12/21 Sumatriptan + Serotonin receptor agonist + Suvexx 2020/07/24 naproxen NSAID Belsomra Hypnotic 2019/04/16 cGMP-specific Tadalafil Adcirca phosphodiesterase type 5 2009/11/25 inhibitor Selective stabilizer of Tafamidis Vyndaqel 2020/04/07 transthyretin - cardiac drug Tamsulosin + Alpha-1 blocker + 5-Alpha Jalyn 2012/02/03 dutasteride reductase inhibitor Tapentadol Nucynta CR Opioid analgesic 2011/03/01 Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Tapentadol Nucynta IR Opioid analgesic 2012/03 Tedizolid Sivextro Oxazolidinone antibiotic 2015/10/08 Telaprevir Incivek Antiviral agent 2011/10/06 Angiotensin II antagonists Telmisartan + Twynsta and calcium channel 2011/08/03 amlodipine blockers Tryptophan hydroxylase Telotristat ethyl Xermelo 2018/10/12 inhibitor Sodium/hydrogen exchanger Tenapanor Ibsrela 2020/11/23 inhibitor Protein kinase inibitor Tepmetko (antineoplastic agent) Aubagio Immunomodulator agent 2013/11/15 Osnuvo Bone formation agent 2020/10/27 Testosterone Natesto Androgen 2016/05/06 Pontocaine Tetracaine (spinal Local anesthetic anesthesia) Thalomid Immunomodulatory agent 2010/08/06 Hormone replacement Tibolone Tibella 2020/07/29 therapy Ticagrelor Brilinta Platelet aggregation inhibitor 2011/06/01 Tiotropium + Inspiolto Bronchodilator combination - 2015/05/29 olodaterol Respimat LAMA plus LABA « first? previous ? 4 5 6 7 8 9 10 11 12 next ? last »

© 2017 BC Drug and Poison Information Centre All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions

Source URL (retrieved on 2021-09-26 03:21): http://www.dpic.org/druglisting/everolimus